These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8775399)

  • 1. The efficacy of hyoscine hydrobromide in reducing side-effects induced during immersion in virtual reality.
    Regan EC; Ramsey AD
    Aviat Space Environ Med; 1996 Mar; 67(3):222-6. PubMed ID: 8775399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The frequency of occurrence and severity of side-effects of immersion virtual reality.
    Regan EC; Price KR
    Aviat Space Environ Med; 1994 Jun; 65(6):527-30. PubMed ID: 8074626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of antimotion sickness drugs.
    Wood CD; Manno JE; Wood MJ; Manno BR; Redetzki HM
    Aviat Space Environ Med; 1987 Sep; 58(9 Pt 2):A262-5. PubMed ID: 3675502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NTP Toxicology and Carcinogenesis Studies of Scopolamine Hydrobromide Trihydrate (CAS No. 6533-68-2) in F344 Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1997 Mar; 445():1-277. PubMed ID: 12594530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Airsickness prevention in helicopter passengers.
    Estrada A; LeDuc PA; Curry IP; Phelps SE; Fuller DR
    Aviat Space Environ Med; 2007 Apr; 78(4):408-13. PubMed ID: 17484344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the neurokinin-1 antagonist GR205171, alone and in combination with the 5-HT3 antagonist ondansetron, hyoscine and placebo in the prevention of motion-induced nausea in man.
    Reid K; Palmer JL; Wright RJ; Clemes SA; Troakes C; Somal HS; House F; Stott JR
    Br J Clin Pharmacol; 2000 Jul; 50(1):61-4. PubMed ID: 10886120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular effects of hyoscine in double dose transdermal administration and its reversal by low dose pyridostigmine.
    Alhalel A; Ziv I; Versano D; Ruach M; Alkalay M; Almog S; Izraeli S; Glovinsky J
    Aviat Space Environ Med; 1995 Nov; 66(11):1037-40. PubMed ID: 8588791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of marezine and dramamine in preventing symptoms of motion sickness.
    Weinstein SE; Stern RM
    Aviat Space Environ Med; 1997 Oct; 68(10):890-4. PubMed ID: 9327113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of cinnarizine and cocculus indicus on simulator sickness.
    Lucertini M; Mirante N; Casagrande M; Trivelloni P; Lugli V
    Physiol Behav; 2007 May; 91(1):180-90. PubMed ID: 17434541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental research on antimotion sickness effects of Chinese medicine "pingandan" pills in cats.
    Pei JS; Tong BL; Chen KJ; Li CS; Zhang GX
    Chin Med J (Engl); 1992 Apr; 105(4):322-7. PubMed ID: 1618017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness.
    Pingree BJ; Pethybridge RJ
    Aviat Space Environ Med; 1994 Jul; 65(7):597-605. PubMed ID: 7945125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S; Shapira S; Zilbiger A; Ribak J
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose ondansetron for reducing motion sickness in highly susceptible subjects.
    Muth ER; Elkins AN
    Aviat Space Environ Med; 2007 Jul; 78(7):686-92. PubMed ID: 17679566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug treatment of motion sickness: scopolamine alone and combined with ephedrine in real and simulated situations.
    Tokola O; Laitinen LA; Aho J; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1984 Jul; 55(7):636-41. PubMed ID: 6466260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy.
    Clissold SP; Heel RC
    Drugs; 1985 Mar; 29(3):189-207. PubMed ID: 3886352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post hoc comparison of daily rates of nausea and vomiting with once- and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study.
    Dunbar F; Zhu Y; Brashear HR
    Clin Ther; 2006 Mar; 28(3):365-72. PubMed ID: 16750451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of serotonin (5-HT3) receptor antagonists on gastric tachyarrhythmia and the symptoms of motion sickness.
    Levine ME; Chillas JC; Stern RM; Knox GW
    Aviat Space Environ Med; 2000 Nov; 71(11):1111-4. PubMed ID: 11086664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.